Food al­ler­gy biotech Al­ladapt clos­es af­ter Phase 3 talks with FDA

Al­ladapt Im­munother­a­peu­tics, a well-fi­nanced biotech work­ing in the food al­ler­gy field, shut down fol­low­ing talks with the FDA, ac­cord­ing to a source fa­mil­iar with the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.